Asymptomatic Bradycardia Associated with Amisulpride

 

 Buy Article Permissions and Reprints

Well-known adverse effects of amisulpride include nausea, insomnia or tiredness, gastrointestinal, extrapyramidal and endocrine symptoms. Cardiac disorders, however, appear to be an extremely rare complication of the drug. Only a few case reports on this complication have been published so far, which deal with QT prolongation, hypotension, hypertension and palpitations. Bradycardia has not yet been mentioned. Here, we will report on a case of asymptomatic bradycardia that developed subsequent to therapeutic doses of amisulpride in a 25-year-old male patient with chronic paranoid-hallucinatory schizophrenia. The patient had been rehospitalized for an acute exacerbation of the psychosis. When the patient failed to respond at the beginning of hospitalization, the treatment was changed from clozapine to amisulpride. After a complete switchover to amisulpride, the patient's ECG showed sinus bradycardia and QT prolongation. When the daily dose of amisulpride was reduced from 800 mg/d to 600 mg/d, the patient's ECG quickly normalized (including blood pressure and pulse rate) within a few days. The patient did not report any cardiovascular-related complaints. Since the cardiovascular-specific diagnostics did not yield any indicative results, bradycardia may be a rare complication of amisulpride treatment.

References

• 1 Agnoli A, Ravizza L, Torta R. Studio controllato in doppio cieco nelle sindromi disimiche (amisulpride versus amitriptilina). Roma; Atti del XXXVII Congresso Nazionale S.I.P.-Roma, 6 - 11 febbraio 1989, Supplemento II. 1989: 1-7
• 2 Bandelow B, Fritze J, Rüther E. Increased mortality in schizophrenia and the influence of antipsychotic treatment.  Intern J Psych Clin Practice. 1998;  2 549-557
  PubMedGoogle Scholar
• 3 Campbell M, Young P J, Bateman D I, Smith J M, Thomas S HL. The use of atypical antipsychotics in the management of schizophrenia.  Br J Clin Pharmacol. 1999;  47 13-22
  CrossrefPubMedGoogle Scholar
• 4 Casey D E. Side effect profiles of new antipsychotic agents.  J Clin Psychiatry. 1996;  57 40-45
  PubMedGoogle Scholar
• 5 Czekalla J, Dittmann R W. EKG-Veränderungen unter Therapie mit konventionellen und neuartigen Psychopharmaka.  Klinikarzt. 1998;  5/27 20-24
  PubMedGoogle Scholar
• 6 Degner D, Rüther E. Atypische Neuroleptika in der Schizophreniebehandlung.  Nervenheilkunde. 1998;  17 472-479
  PubMedGoogle Scholar
• 7 Grohmann R, Rüther E, Engel R R, Hippius H. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: Methods and first results on tricyclic antidepressants and SSRI.  Pharmacopsychiatry. 1999;  32 21-28
  PubMedGoogle Scholar
• 8 Große Aldenhövel H, Heusler H, Gallenkamp U. Bradycardia to Biperiden.  Pharmacopsychiatry. 1989;  22 (1) 42-43
  PubMedGoogle Scholar
• 9 Guthrie S K, Manzey L, Scott D, Giordani B, Tandon R. Comparison of central and peripheral pharmacological effect sof biperiden and trihexyphenidyl in human volunteers.  J Clin Psychopharmacol. 2000;  20 (1) 77-83
  CrossrefPubMedGoogle Scholar
• 10 Harry P. Acute poisoning by new psychotropic drugs.  Rev Prat. 1997;  47 731-735
  PubMedGoogle Scholar
• 11 Hayano T, Shimizu A, Ikeda Y, Yamamoto T, Yamagata T, Ueyama T, Furutani Y, Matsuzaki M. Paradoxical effects of pirenzepine on parasympathetic activity in chronic heart failure and control.  Int J Cardiol. 1999;  68 (1) 47-56
  CrossrefPubMedGoogle Scholar
• 12 Louwerens J W, Ramaekers J, de Brie A, Muntjewerff N, Rosenzweig P, O'Hanlon J F. Haloperidol and amisulpride cause different side-effects and negative symptoms in healthy volunteers.  Biol Psychiatry. 1997;  42 231
  PubMedGoogle Scholar
• 13 Möller H J, Boyer P, Fleurot O, Rein W. Verbesserungen akuter Exazerbationen der Schizophrenie mit Amisulprid: ein Vergleich mit Haloperidol.  Psychopharmacology. 1997;  132 396-401
  CrossrefPubMedGoogle Scholar
• 14 Möertl D, Heiden A, Porenta G, Kasper S. Kardiovaskuläre Nebenwirkungen bei Neuroleptikatherapie.  Psychopharmakotherapie. 1998;  3 (5) 109-114
  PubMedGoogle Scholar
• 15 Puech A, Fleurot O, Rein W. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia a dose-ranging study vs. Haloperidol.  Acta Psychiatr Scand. 1998;  98 65-72
  CrossrefPubMedGoogle Scholar
• 16 Speller J C, Barnes T RE, Curson D A, Pantelis C, Alberts J L. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterized by persistent negative symptoms (Amisulpride vs. Haloperidol).  Br J Psychiatry. 1997;  171 564-568
  PubMedGoogle Scholar
• 17 Tracqui A, Mutter-Schmidt C, Kintz P, Berton C, Mangin P. Amisulpride poisoning: a report on two cases.  Human & Experimental Toxicology. 1995;  14 294-298
  PubMedGoogle Scholar

Francisco Pedrosa GilM.D. 

Department of Psychiatry
Max-Planck-Institute of Psychiatry

Kraepelinstraße 2 - 10
80804 Munich
Germany

Phone: + 49-89-30622-524

Fax: + 49-89-30622-461

Email: pedrosa@mpigsykl.mpg.de